 control trial interferon gamma infect chronic granulomat diseas intern chronic granulomat diseas cooper studi group background chronic granulomat diseas uncommon inherit disord phagocyt defect product reactiv intermedi oxygen predispos patient pyogen infect evid vitro vivo studi interferon gamma metabol defect phagocyt efficaci interferon gamma frequenc seriou infect patient diseas method double-blind placebo-control studi patient chronic granulomat diseas median age year patient interferon gamma microgram squar meter body-surfac area placebo time week year primari end point studi time first seriou infect event hospit parenter antibiot measur phagocyt function result term time first seriou infect clear benefit interferon placebo patient seriou infect patient reduct total number seriou infect interferon placebo interferon benefici regardless age use nonus prophylact antibiot mode inherit x-link autosom recess signific chang measur superoxid product phagocyt interferon therapi evid seriou toxic conclus patient chronic granulomat diseas interferon gamma therapi effect well-toler treatment frequenc seriou infect